Wnt family member 10BGenealiases: SHFM6 · STHAG8 · WNT-12
Q-omics provides the consensus-scored WNT10B profile across patient tissues and cancer cell-line models. WNT10B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, WNT10B is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, WNT10B RNA expression shows 15,171 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BLCA, and UVM as cancer lineages where WNT10B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WNT10B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WNT10B survival associations across molecular data types. WNT10B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WNT10B RNA expression–survival associations across cancer types. High WNT10B expression shows unfavorable associations in KIRC, UVM, COAD, ACC and MESO, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for WNT10B RNA expression.
This table summarizes WNT10B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for WNT10B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WNT10B shows lower tumor expression in BLCA, THCA and BRCA and higher tumor expression in LUSC, KIRC and LUAD. The BLCA box plot shows higher WNT10B RNA expression in normal versus tumor tissue (log2 FC = −1.440, t-test p < 0.001).
This table shows molecular features associated with WNT10B in patient tissues and cancer cell lines. In patient samples, WNT10B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, WNT10B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
